Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW fluorescence-guided surgery dose-finding in soft tissue sarcoma
NL-OMON47633Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab-IRDye800CW in soft tissue sarcoma (STS) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Intraoperative assessment of positive margins based on fluorescence imaging, Ex vivo specimen imaging for positive margins and 3 more. Started Apr 2019; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON47633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47633.